Business Context and Reporting Period
Company: 111, Inc. (Nasdaq: YI)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: 111, Inc. is a Cayman Islands holding company operating primarily through PRC subsidiaries. It operates an integrated online and offline healthcare platform in China, comprising "1 Medicine Marketplace" (B2C retail pharmacy) and "1 Pharmacy" (B2B wholesale pharmacy). The company connects pharmaceutical companies, pharmacies, and consumers, offering products ranging from prescription drugs to health and wellness items, alongside value-added services like online consultations and supply chain solutions.
Corporate Structure: The company transitioned from a Variable Interest Entity (VIE) structure to direct equity ownership of its PRC operating subsidiaries in February 2022. It maintains a dual-class share structure where Class B shares (held by founders) carry 15 votes per share, while Class A shares carry 1 vote per share.
Key Financial Metrics (2024 vs. 2023)
| Metric | 2024 (RMB) | 2024 (US$) | 2023 (RMB) | Change |
|---|---|---|---|---|
| Total Net Revenues | 14,401,249 | 1,972,963 | 14,948,129 | -3.7% |
| Net Loss | (20,776) | (2,847) | (353,433) | 94.1% Improvement |
| Operating Income | 2,114 | 289 | (350,097) | Turned Profitable |
| Operating Cash Flow | 263,016 | 36,033 | (447,244) | Positive vs. Negative |
| Cash & Equivalents | 462,289 | 63,333 | 603,523 | -23.4% |
| Short-term Borrowings | 160,981 | 22,054 | 338,075 | -52.4% |
Note: US$ amounts are translated at the rate of RMB 7.2993 to US$1.00 as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total net revenues decreased 3.7% to RMB 14.4 billion. This was driven by a 3.1% decline in B2B product revenues (RMB 14.0 billion) and a significant 27.0% decline in B2C product revenues (RMB 261 million), attributed to unfavorable macroeconomic conditions.
- Profitability Improvement: The company narrowed its net loss significantly from RMB 353.4 million in 2023 to RMB 20.8 million in 2024. Operating income turned positive at RMB 2.1 million, compared to an operating loss of RMB 350.1 million in 2023.
- Expense Reduction: Operating costs and expenses decreased 5.9% to RMB 14.4 billion. Notable reductions included:
- Selling & Marketing: Decreased 30.0% to RMB 313.9 million.
- General & Administrative: Decreased 68.4% to RMB 70.9 million, largely due to reduced share-based compensation.
- Technology Expenses: Decreased 44.0% to RMB 69.6 million.
- Cash Flow Reversal: The company generated positive operating cash flow of RMB 263.0 million in 2024, a reversal from the RMB 447.2 million outflow in 2023. This was driven by a decrease in accounts receivable and an increase in accounts payable.
Guidance, Outlook, Risks, and Contingencies
- Redeemable Non-Controlling Interests (NCI): A significant contingent liability exists related to investors in the subsidiary "1 Pharmacy Technology." If the subsidiary fails to complete a qualified IPO (STAR Market listing) by the agreed date, investors have the right to redeem their equity at cost plus 6% annual interest. As of December 31, 2024, RMB 1.08 billion is recorded as redeemable NCI. The company has reached agreements with investors representing ~96.79% of this amount to reschedule repayments over extended periods.
- Going Concern: The auditor's report for 2023 raised substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and the potential redemption obligation. Management asserts that positive operating cash flow in 2024 and secured credit facilities mitigate this risk for the next 12 months.
- Regulatory Risks: The company faces significant risks related to PRC regulations, including:
- HFCAA: Potential delisting risks if the PCAOB cannot inspect auditors in China for two consecutive years (currently resolved for 2022, but ongoing uncertainty).
- CSRC Filing: New requirements for PRC companies listing overseas may require future filings with the China Securities Regulatory Commission.
- Data Security: Evolving cybersecurity and data privacy laws in China could increase compliance costs or restrict operations.
- Dividend Policy: The company has not paid dividends and does not plan to do so in the near future, intending to retain earnings for operations and expansion.
Key Facts for Investor Verification
- Redemption Obligation Status: Verify the current status of the RMB 1.08 billion redemption obligation for 1 Pharmacy Technology investors and the enforceability of the rescheduling agreements.
- Going Concern Assessment: Confirm management's ability to sustain positive operating cash flows and service debt obligations given the historical losses and contingent liabilities.
- Regulatory Compliance: Monitor developments regarding the PCAOB inspection status and CSRC filing requirements for overseas-listed Chinese companies.
- B2C Segment Performance: Investigate the causes of the 27% decline in B2C revenue and the company's strategy to reverse this trend.
- Share-Based Compensation: Note the significant reduction in share-based compensation expenses in 2024 (down from RMB 226 million in 2023 to RMB 20 million), which heavily influenced the net loss reduction.